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Background: Exome sequencing has become more and more affordable and the technique has emerged as an
important diagnostic tool for monogenic disorders at early stages of investigations, in particular when clinical
information is limited or unspecific as well as in cases of genetic heterogeneity.
Methods: We identified a consanguineous Pakistani family segregating an autosomal recessive phenotype
characterized by muscular hypertrophy, mild mental retardation and skeletal abnormalities. The available clinical
information was incomplete and we applied whole exome sequencing in an affected family member for the
identification of candidate gene variants.
Results: Exome sequencing identified a previously unreported homozygous mutation in the acceptor splice site
of intron 5 in the BSCL2 gene (c.574-2A > G). Expression analysis revealed that the mutation was associated with
skipping of exon 6. BSCL2 mutations are associated with Berardinelli-Seip congenital lipodystrophy and a clinical
re-evaluation of affected individuals confirmed the diagnosis.
Conclusions: Exome sequencing is a powerful technique for the identification of candidate gene variants in Mendelian
traits. We applied this technique on a single individual affected by a likely autosomal recessive disorder without
access to complete clinical details. A homozygous and truncating mutation was identified in the BSCL2 gene
suggesting congenital generalized lipodystrophy. Incomplete phenotypic delineations are frequent limiting factors in
search for a diagnosis and may lead to inappropriate care and follow-up. Our study exemplifies exome sequencing
as a powerful diagnostic tool in Mendelian disorders that may complement missing clinical information and accelerate
clinical diagnosis.
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Mutation detection in genetic diseases is important for a
definite diagnosis for genetic counseling, future prenatal
diagnosis and therapy. Next generation sequencing tech-
nologies are increasingly being used as a diagnostic tool
for genetic disorders and have been shown particularly
successful in genetically heterogeneous phenotypes, or
when ascertainment of clinical features and symptoms
are unattainable [1-10]. Furthermore, exome sequencing* Correspondence: joakim.klar@igp.uu.se
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unless otherwise stated.is in many cases a cost-effective diagnostic method of
patients with Mendelian traits compared to the interro-
gation of candidate genes one by one.
We report herein on a family segregating short and
muscular stature, mild mental retardation and acromeg-
alic appearance as an autosomal recessive trait. The clin-
ical information was otherwise sparse. Using whole
exome sequencing (WES), we identified a homozygous
mutation in the acceptor splice site of intron 5 of the
BSCL2 gene previously associated to congenital general-
ized lipodystrophy type 2 (CGL2) [11]. Functional ana-
lysis revealed that the mutation results in a complete
skipping of exon 6 leading to a predicted change inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Clinical re-evaluation of the patients confirmed the diag-
nosis congenital generalized lipodystrophy.
Methods
Study subjects
We identified a consanguineous six generation Pakistani
pedigree with three members, two females and one
male, who presented with similar features. The pedigree
structure suggested an autosomal recessive inheritance
(Figure 1A). The family lived in an isolated rural area
and the initial clinical data was scanty with information
on muscular hypertrophy, mild mental retardation, and
possible skeletal malformations. The diagnosis remained
unclear and further clinical information and laboratory
data were unavailable. Informed consent was obtained
from all individuals who participated in this study or
their legal guardian under a protocol approved by the
local ethical committee at National Institute for Biotech-
nology and Genetic Engineering (NIBGE), Faisalabad,
Pakistan. This includes consent from the patients to pub-
lish images.
Exome sequencing and mutation detection
DNA from an affected individual (V3) was sonicated
using a Covaris S2 instrument (Covaris, Inc., Woburn,Figure 1 Pedigree of family segregating Berardinelli-Seip congenital l
indicating consanguinity and autosomal recessive inheritance. Haplotypes s
are shown below each symbol. The mutation segregates within a shared h
variant is predicted to lead to an exon skipping of exon 6, which would result
C) Chromatogram showing cDNA sequences obtained from expressed min
without the variant. The variant is situated within the acceptor splice site
co-transfection of w.t. and mutant construct (middle) and mutated construMA, USA). Fragment libraries were created from the
sheared samples using the AB Library Builder System
(Life Technologies, Carlsbad, California, USA) and target
enrichment was performed using the Agilent SureSelect
Human All Exon v4 kit according to the manufacturer's
protocols (Agilent, Santa Clara, CA, USA). Exome cap-
ture was conducted by hybridizing the DNA libraries
with biotinylated RNA baits for 24 h followed by extrac-
tion using streptavidin coated magnetic beads. Captured
DNA was then amplified followed by emulsion PCR
using the EZ Bead System (Life Technologies) and
sequenced on the SOLiD5500xl system, generating
over 100 million reads of 75 bp length for each of the
samples. Alignment of reads to the human reference
sequence (hg19 assembly) and variant detection was
performed using v2.1 of the LifeScope Software (Life
Technologies). SNPs and indel data was stored in an
in-house exome database together with variant annota-
tion information obtained from ANNOVAR [12] and
dbSNP137. Custom R scripts were used to identify po-
tentially damaging variants not present in any of ~800
exomes from our in-house database. A minimal sequence
depth of x5 was used as a quality cut-off. The BSCL2
variant was confirmed by direct sequencing with dideoxy
chain-termination method (Applied Biosystems BigDye
Terminator v3.1 Cycle Sequencing Kit) on a 3730xl DNAipodystrophy and a BSCL2 splice site mutation. A) Family structure
panning the BSCL2 gene mutation (c.574-2A > G) on chromosome 11
omozygous (autozygous) region in all affected individuals. B) The
s in a frameshift and premature termination of the protein (p.Y256fsX48).
i-gene constructs containing BSCL1 gene spanning exons 5–7, with or
of intron 5 of the BSCL2 gene. Wild-type (w.t.) BSCL1 construct (top),
ct (bottom).
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analysis was performed using the Sequencer software
(Gene Codes Corporation, Ann Arbor, MI, USA).
Minigene expression construct
In total, 5 μg of genomic DNA from a heterozygous in-
dividual (VI:1) was used for amplification with primers
BSCL2 e5F (GTG ATG CTG CAT TAC CGC TCA
GAC) and BSCL2 e7R (CTG CAA AGA GAA GCG
GTG TCG G). The PCR product was re-amplified using
primers BSCL2 e5F Hind III (AGC TCA AGC TTC
GTG ATG CTG CAT TAC CGC TCA GAC) and
BSCL2 e7R Kpn I (CCC GCG GTA CCG CTG CAA
AGA GAA GCG GTG TCG G) to introduce restriction
sites. The resulting PCR product was cloned into a TA
cloning vector (Invitrogen, Carlsbad, CA, USA) and in-
dividual clones were analyzed by Sanger sequencing.
Clones representing the two alleles (wt allele (ag) and
mutant allele (gg)) were identified and subsequently
inserted into a pEGFP-C2 expression vector (Clontech,
Mountain View, CA, USA) using Hind III, Kpn I and
Rapid DNA ligation kit (Fermentas, Thermo Fisher
Scientific, Waltham, MA, USA) and confirmed by sequen-
cing. Thus, the minigene was fused to green fluorescent
protein (Additional file 1: Figure S1A).
Splicing assay
The two minigene expression constructs were transfected
into HEK293T cells using FuGene® Transfection reagent
following manufacturer’s recommendations (Promega,
Fitchburg, WI, USA). Cells were grown in DMEM supple-
mented with 10% fetal calf serum, 2 mM L-glutamine,
20 IU penicillin/streptomycin and non-essential amino
acids (all Sigma-Aldrich, St. Louis, MI, USA) at 37°C with
5% CO2 in a humidified atmosphere. Expression of the
GFP-minigene was confirmed by fluorescence microscopy
after 48 hours. Subsequently, cells were harvested and total
RNA was isolated using TRIZOLTM (Invitrogen), following
the manufacturer’s protocols. Splicing of the minigene was
detected by reverse transcription of 2 μg of total RNA
using oligo-d(T) primers, utilizing the VILO cDNA syn-
thesis kit (Invitrogen). Splicing products were amplified
by standard PCR with primers Assay Forward (TAC
AAG TCC GGC CGG ACT CAG ATC) and BSCL2
e7R (Additional file 1: Figure S1B). PCR products were
cloned into a TA cloning vector (Invitrogen), and indi-
vidual clones were analyzed by Sanger sequencing.
Results
Genetic analysis
Targeted enrichment of DNA from one affected family
member, followed by WES and filtering, identified 34
homozygous variants, including one in the BSCL2 gene
(NG_008461.1; NM_032667.6) (Additional file 2: Table S1).The sequencing resulted in 97% target base coverage (>1X)
and 85% of the target bases were covered >20X. The
variant is situated in the acceptor splice site of intron
5 (c.574-2A > G) of the gene and predicts skipping of
exon 6 with a frameshift and premature termination
codon (p.Y256fsX48) (Figure 1B). Sanger sequencing
confirmed homozygosity for the c.574-2A > G variant in
all three affected members (V:3, V:5 and VI:2) whereas
three available parents were heterozygous (Figure 1A,C).
Furthermore, the variant was excluded on 200 Swedish
and 200 Pakistani control chromosomes and is not pre-
sent in 6503 exomes from the Exome Variant Server,
NHLBI GO Exome Sequencing Project (ESP), Seattle,
WA (URL: http://evs.gs.washington.edu/EVS/). Segregation
of a homozygous region surrounding the BSCL2 variant
was confirmed using microsatellite markers (Figure 1A).
Study subjects
The family was revisited after WES analysis for a clinical
re-evaluation of the three affected family members.
The investigation revealed generalized lipodystrophy,
axillary acanthosis nigricans relatively large hands and
feet, muscular hypertrophy and acromegaloid appearance
(Figure 2). The three affected individuals had mental re-
tardation and individual V:5 had type 2 diabetes and a
spastic gait suggesting upper motor neuron involvement.
None of the three affected members had signs of muscle
weakness. Hearing was normal. The proband (V:3) was
available for ultrasound investigation and biochemical
analysis. Ultrasound of abdomen showed enlarged liver
(16.5 cm) and spleen (13.5 cm). Biochemical analysis of
serum revealed increased levels of alanine aminotransfer-
ase levels (ALT; 64 U/L) and increased alkaline phosphat-
ase levels (328 U/L). Unexpectedly, S-triglyceride and
cholesterol levels were within the upper normal range
as well as fasting glucose levels. The combined findings
from our re-investigation of the family confirmed con-
genital generalized lipodystrophy.
Functional analysis
To evaluate the predicted effects of the acceptor splice
site mutation in intron 5 of the BSCL2 gene, we created
a mini-gene consisting of exon 5 through exon 7 includ-
ing the two introns, fused to green fluorescent protein
(Additional file 1: Figure S1A). Mini-genes containing
the wild-type (wt; ag) and mutated (gg) splice site vari-
ants, respectively, were expressed in HEK293T cells and
RNA was isolated 48 h after transfection. The amplified
spliced products were analyzed by agarose gel electro-
phoresis and we observed a band of expected size from
the wt construct (420 bp) whereas a shorter product
(322 bp) was generated when amplifying from the mu-
tated construct (Additional file 1: Figure S1B). The PCR
products were cloned and analyzed by sequencing that
Figure 2 Clinical features of the patients. A-C) The affected family member V:3 illustrating muscular stature (A, B) acromegalic appearance (C)
and axillary acanthosis nigricans (D).
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file 1: Figure S1C).
Discussion
We identified a consanguineous family segregating auto-
somal recessive muscular hypertrophy mild mental retard-
ation and acromegaloid appearance in three individuals.
Detailed clinical and biochemical data were unavailable
and we decided to performWES on a single affected family
members in search for homozygous and potentially dam-
aging gene variants. Analysis of WES data showed a homo-
zygous acceptor splice site mutation, c.574-2A >G, in
intron 5 of the BSCL2 gene. The BSCL2 gene is associated
with congenital generalized lipodystrophy type 2 (CGL2)
and, indeed, clinical re-evaluation of our patients con-
firmed characteristic clinical features of the disease in all
three affected members [11]. Taken together the deleteri-
ousness of the variant in BSCL2 and the clinical overlapwith the preliminary information we had of the family, this
was considered the most likely candidate variant of the
ones indentified. Furthermore, we could by using a mini-
gene construct spanning exons 5–7 of the mutated BSCL2
allele show that the mutation results in skipping of exon 6,
an altered reading frame and a predicted early termination
of the protein. Individuals with CGL2 can usually be recog-
nized at birth, or soon thereafter, due to a near-total lack of
body fat and prominent muscularity. Later characteristics
include insulin resistance, hypertriglyceridemia, hepatic
steatosis and early onset of diabetes. A high prevalence
of mild to moderate intellectual impairment has been
observed and patients have a higher risk for premature
mortality, mainly due to cardiac failure. Additional fea-
tures include acanthosis nigricans, hepatomegaly, hyper-
androgenism and skeletal muscular hypertrophy [13,14].
The disorder may, however, be mistaken for other types
of lipodystrophies, especially in adult stage, making a
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forts have been made in the characterization and identifi-
cation of the molecular basis of inherited lipodystrophies,
and to date at least 11 gene-loci are known [13].
In our family, the initial information suggested a disab-
ling condition segregating as an autosomal recessive
trait. The clinical data were insufficient for a diagnosis
and further investigations of the family were impossible
within a reasonable time-frame. Thus, we decided to apply
WES and, from our findings, we were able to suggest that
the patients were affected by CGL2 within a few weeks
from the sampling of DNA. Much later, the diagnosis was
confirmed through directed clinical and biochemical in-
vestigations of the family. Moreover, this exemplifies a
time-saving aspect of exome sequencing in situations of
diagnostic challenges, inaccessible clinical data as well as
acute illnesses [13]. Furthermore, rare diseases such as
CGL2 may remain undiagnosed due to socio-economic
constraints and inaccessible health care. Under such cir-
cumstances exome sequencing may become an attractive
diagnostic complement with a continuous reduction in
price. In a clinical setting, an alternative to WES could be
the use of targeted sequencing of a specific subset of genes
responsible for a certain condition. Although we are lim-
ited to clinically available disease-targeted enrichment
tests, the resulting data generally have a much higher or
often complete coverage of the targets [19].
Taken together, our results show the usefulness of
WES for the identification of a single homozygous BSCL2
mutation in a family segregating an autosomal recessive
trait. The mutation was analyzed in a cell-based assay that
confirmed exon skipping. Using the findings from WES we
could suggest the diagnosis of CGL2 in advance of
complete clinical information from the patients. The use of
exome sequencing accelerated and facilitated the subse-
quent and confirming investigations, with implications for
care and follow-up of affected individuals.
Conclusions
This study illustrates how whole exome sequencing (WES)
can be used in a clinical setting to identify gene mutations
in search for a specific diagnosis. We show that WES can
be used to accelerate clinical investigations of heteroge-
neous Mendelian traits for yet inconclusive cases.
Additional files
Additional file 1: Figure S1. A) Minigene construct consisting of exon
5 through to exon 7 of the BSCL2 gene, including the introns, fused to
green fluorescent protein (GFP). Two minigenes representing wt (ag) and
mutated (gg) splice site were used. B) PCR based assay of the minigenes.
An observed band of expected size in the wt construct (420 bp), but a
smaller product (322 bp) corresponding to the expected exon skipping
could be identified from the mutated construct. C) Sanger sequencing of
cDNA from mutated (gg) construct confirms skipping of exon 6.Additional file 2: Table S1. Homozygous variants identified by WES.
*snp137 indicates if the variant is present in the 137 version of dbSNP.
Note that presented variants, besides the identified variant in the BSCL2
gene, are not confirmed by Sanger sequencing, and could thereby
possibly be sequencing errors.
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